Back to homepage

Dermatology

Onset of vitiligo following targeted therapy for BRAFV600E-mutated melanoma: case report

Authors: Sonia Brugnara MD, Mariacristina Sicher MD, Elena Maria Bonandini MD, Mattia Barbareschi MD, Carlo Renè Girardelli MD, Orazio Caffo MD

This case study covers a patient who received dabrafenib and trametinib and developed vitiligo-like depigmentation after treatment cessation.

More

Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature

Authors: Pietro Sollena MD, Maria Mannino MD, Francesco Tassone MD, Maria Alessandra Calegari MD, Ettore D’Argento MD, Ketty Peris MD

The authors tested the effectiveness of topical timolol 0.5% gel on paronychia and periungual pyogenic granuloma-like lesions being treated with EGFR-I and reviewed the available literature on this topic, which is the use of topical β-blockers in the management of EGFR-I-induced nail toxicities.

More

Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research

Authors: Stefania Nicola MD, Giovanni Rolla MD, Luisa Brussino MD

This review focuses on the mechanisms of action, routes of administration, and efficacy of therapies for the rare genetic disorder hereditary angioedema.

More

Guselkumab for the treatment of psoriasis – evidence to date

Authors: Miguel Nogueira MD, Tiago Torres MD, PhD

This review highlights the evidence available to date for the use of guselkumab for the treatment of psoriasis. The results of the recent ECLIPSE trial are addressed.

More

Brodalumab in psoriasis: evidence to date and clinical potential

Authors: Amy C Foulkes BMedSci (Hons), BMBS, MRCP (Derm), PhD, Richard B Warren BSc (Hons), MBChB (Hons), MRCP, PhD

This article reviews brodalumab’s place in the expanding armamentarium of cytokine-directed therapies for patients with severe psoriasis.

More